<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747642</url>
  </required_header>
  <id_info>
    <org_study_id>OP2</org_study_id>
    <nct_id>NCT01747642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma</brief_title>
  <official_title>Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Organization, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Research Organization, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oncoxin in combination with Surafenib is safe and results in improved survival in patients
      with hepatocellular carcinoma (HCC)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular
      carcinoma

      To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma
      patients after administration of Oncoxin plus Surafenib

      To see if there is reduction tumor size and or number in hepatocellular carcinoma patients
      after administration of Oncoxin plus Surafenib

      To see if there is improvement of quality of life in hepatocellular carcinoma patients after
      administration of Oncoxin plus Surafenib

      To see if there is improved survival in hepatocellular carcinoma patients after
      administration of Oncoxin plus Surafenib
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who have prolonged survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in serum alpha-fetoprotein level and decrease in tumor size</measure>
    <time_frame>24 weeks</time_frame>
    <description>To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Oncoxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncoxin &amp; Suranix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oncoxin</intervention_name>
    <description>Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days</description>
    <arm_group_label>Oncoxin</arm_group_label>
    <arm_group_label>Oncoxin &amp; Suranix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suranix</intervention_name>
    <description>Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days</description>
    <arm_group_label>Oncoxin &amp; Suranix</arm_group_label>
    <other_name>Nexavar</other_name>
    <other_name>Suranib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HCC irrespective of etiology, age, gender and status of underlying liver
             disease.

          -  Patients with HCC who are not suitable candidates for established modalities of
             treatment i.e. surgery and/or chemotherapy.

          -  Patients with HCC who have evidence of tumor metastasis

          -  Patients with HCC who are voluntarily unwilling to take established modalities of
             treatment i.e. surgery and/or chemotherapy.

          -  Patients with HCC in whom all possible treatment options have been exhausted.

        Exclusion Criteria:

          -  Patients with HCC who are suitable candidates for established modalities of treatment
             i.e. surgery and/or chemotherapy.

          -  Patients with HCC who have no evidence of tumor metastasis

          -  Patients with HCC who are willing to take established modalities of treatment i.e.
             surgery and/or chemotherapy.

          -  Patients with HCC who are voluntarily unwilling to be included in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mamun A Mahtab, MD, FACG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Farabi General Hospital</name>
      <address>
        <city>Dhaka</city>
        <zip>1215</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamun A Mahtab, MD, FACG</last_name>
      <phone>+8801711567275</phone>
      <email>shwapnil@agni.com</email>
    </contact>
    <contact_backup>
      <last_name>Helal Uddin, BSc</last_name>
      <phone>+880-1819251514</phone>
      <email>crobangladesh@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mamun A Mahtab, MD, FACG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lovely Begum, BPharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2012</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Oncoxin</keyword>
  <keyword>Surafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

